Strengthening HPV Immunization Through EPI Leveraged Delivery

This is a randomized observer-blind placebo-controlled proof-of-concept study with the aim to assess the safety and tolerability, and the immunogenicity of a bivalent HPV vaccine administered in healthy infants and toddlers (9- and 15-month-olds) comparing them to an immune-bridging population of 15-20-year-old unmarried females in an open label study in Ghana at the Dodowa Health Research Center.

NCT Number	NCT07377656
Lead Sponsor	International Vaccine Institute Collaborators: Karolinska Institutet, Noguchi Memorial Institute for Medical Research, Dodowa Health Research Centre
Conditions	HPV Vaccine
Enrollment	115 participants
Start Date	2026-04-30
Primary Completion	2028-02-29 (estimated)
Study Completion	2028-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-18